Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2005-02-09
2010-12-28
Chong, Kimberly (Department: 1635)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C536S024310, C536S024100, C435S006120, C435S325000, C435S375000, C514S04400A
Reexamination Certificate
active
07858769
ABSTRACT:
The present invention concerns methods and nucleic acid based reagents useful in modulating gene expression in a variety of applications, including use in therapeutic, veterinary, agricultural, diagnostic, target validation, and genomic discovery applications. Specifically, the invention relates to multifunctional short interfering nucleic acid (multifunctional siNA) molecules that modulate the expression of one or more genes in a biologic system, such as a cell, tissue, or organism via RNA interference (RNAi). The bifunctional short interfering nucleic acid (multifunctional siNA) molecules of the invention can target more than one regions of nucleic acid sequence in a single target nucleic acid molecule or can target regions of nucleic acid sequence in differing target nucleic acid molecules. The self multifunctional siNA molecules are useful in the treatment of any disease or condition that responds to modulation of gene expression or activity in a cell, tissue, or organism.
REFERENCES:
patent: 5587471 (1996-12-01), Cook et al.
patent: 5814620 (1998-09-01), Robinson et al.
patent: 5898031 (1999-04-01), Crooke
patent: 5998148 (1999-12-01), Bennett et al.
patent: 5998203 (1999-12-01), Matulic-Adamic et al.
patent: 5998206 (1999-12-01), Cowsert
patent: 6060456 (2000-05-01), Arnold et al.
patent: 6107094 (2000-08-01), Crook
patent: 6214805 (2001-04-01), Torrence et al.
patent: 6346398 (2002-02-01), Pavco et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 6573099 (2003-06-01), Graham et al.
patent: 6824972 (2004-11-01), Kenwrick et al.
patent: 7022828 (2006-04-01), McSwiggen et al.
patent: 7078196 (2006-07-01), Tuschl et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0151693 (2002-10-01), Breaker et al.
patent: 2003/0059944 (2003-03-01), Lois-Caballe et al.
patent: 2003/0064945 (2003-04-01), Akhtar et al.
patent: 2003/0083294 (2003-05-01), Sullenger et al.
patent: 2003/0143732 (2003-07-01), Fosnaugh et al.
patent: 2003/0190635 (2003-10-01), McSwiggen et al.
patent: 2003/0206887 (2003-11-01), Morrissey et al.
patent: 2004/0019001 (2004-01-01), McSwiggen et al.
patent: 2004/0053876 (2004-03-01), Turner et al.
patent: 2004/0161844 (2004-08-01), Baker et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0020521 (2005-01-01), Rana
patent: 2005/0182005 (2005-08-01), Tuschl et al.
patent: 2005/0227256 (2005-10-01), Hutvagner et al.
patent: 2001240375 (2001-03-01), None
patent: 2359180 (2000-08-01), None
patent: 1144623 (2002-01-01), None
patent: 1325955 (2002-01-01), None
patent: 1389637 (2002-08-01), None
patent: 08208687 (1996-08-01), None
patent: 90/14090 (1990-11-01), None
patent: 94/01550 (1994-01-01), None
patent: 95/04142 (1995-02-01), None
patent: 99/04819 (1999-02-01), None
patent: 99/07409 (1999-02-01), None
patent: 99/14226 (1999-03-01), None
patent: 99/32619 (1999-07-01), None
patent: 99/49029 (1999-09-01), None
patent: 99/53050 (1999-10-01), None
patent: 99/55857 (1999-11-01), None
patent: 99/61631 (1999-12-01), None
patent: 00/01846 (2000-01-01), None
patent: 00/21560 (2000-04-01), None
patent: 00/44895 (2000-08-01), None
patent: 00/44914 (2000-08-01), None
patent: 00/49035 (2000-08-01), None
patent: 00/63364 (2000-10-01), None
patent: 01/04313 (2001-01-01), None
patent: 01/29058 (2001-04-01), None
patent: 01/36646 (2001-05-01), None
patent: 01/38551 (2001-05-01), None
patent: 01/42443 (2001-06-01), None
patent: 01/49844 (2001-07-01), None
patent: 01/53475 (2001-07-01), None
patent: 01/68836 (2001-09-01), None
patent: 01/70944 (2001-09-01), None
patent: 01/70949 (2001-09-01), None
patent: 01/72774 (2001-10-01), None
patent: 01/75164 (2001-10-01), None
patent: 01/92513 (2001-12-01), None
patent: 01/96584 (2001-12-01), None
patent: 01/97850 (2001-12-01), None
patent: 02/07747 (2002-01-01), None
patent: 02/55692 (2002-01-01), None
patent: 02/55693 (2002-01-01), None
patent: 02/10378 (2002-02-01), None
patent: 02/22636 (2002-03-01), None
patent: 02/38805 (2002-05-01), None
patent: 02/44321 (2002-06-01), None
patent: 03/044188 (2002-11-01), None
patent: 02/096927 (2002-12-01), None
patent: 03/064625 (2003-08-01), None
patent: 03/064626 (2003-08-01), None
patent: 03/068797 (2003-08-01), None
patent: 03/070887 (2003-08-01), None
patent: 03/070896 (2003-08-01), None
patent: 03/070910 (2003-08-01), None
patent: 03/070918 (2003-08-01), None
patent: 03/074654 (2003-09-01), None
patent: 03/080638 (2003-10-01), None
patent: 2004/029212 (2004-04-01), None
patent: 2004/043977 (2004-05-01), None
patent: 2004/048566 (2004-06-01), None
patent: 2004/072261 (2004-08-01), None
patent: 2004/090105 (2004-10-01), None
patent: 2005/019453 (2005-03-01), None
patent: 2005/049821 (2005-06-01), None
Caplen NJ. RNAi as a Gene Therapy Approach. Expert Opinon. Biol. Thera. (2003) vol. 3(4) 575-586. Ashley Publications Ltd.
Parrish et al. Functional Anatomy of a dsRNA trigger: differential requirements for the two trigger strands in RNA interference. Molecular Cell, 2000, vol. 6: 1077-1087.
Braasch et al. Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression. Biochemistry 2002, Vo. 41(14): 4503-4510.
Pieken et al. Kinetic Characterization of Ribonuclease-Resistant 2′-Modified Hammerhead Ribozymes. Science, 1991, vol. 253: pp. 314-317.
Adah et al., “Chemistry and Biochemistry of 2′,5′-Oligoadenylate-Based Antisense Strategy,”Current Medicinal Chemistry, 8, 1189-1212 (2001).
Alexeev et al., “Localized in vivo genotypic and phentypic correction of the albino mutation in skin by Rna-Dna oligonucleotide,”Nature Biotechnology, 18:43-47 (2000).
Bahramian et al., “Transcriptional and Posttranscriptional Silencing of Rodent α1(I) Collagen by a Homologous Transcriptionally Self-Silenced Transgene,”Molecular and Cellular Biology, 274-283 (1999).
Bass, “Double-Stranded RNA as a Template for Gene Silencing,”Cell, 101, 235-238 (2000).
Bass, “The short answer,”Nature411:428-429 (2001).
Bayard et al., “Increased stability and antiviral activity of 2′-O-phosphoglyceryl derivatives of (2′-5′)oligo(adenylate),”Eur. J. Biochem., 142(29):291-298 (1984).
Beigelman et al., “Chemical Modification of Hammerhead Ribozymes,”The Journal of Biological Chemistry270:25702-25708 (1995).
Bellon et al., “4-Thio-oligo-β-D-ribonucleotides: synthesis of β-4′-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase,”Nucleic Acids Research, 21(7):1587-1593 (1993).
Bernstein et al., “Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference,” Nature 409:363-366 (2001).
Bernstein et al., “The rest is silence,”RNA, 7:1509-1521 (2001).
Bitko et al., “Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses,”BMC Microbiology, 1:34 (11 pgs) (2001).
Braasch et al., “Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression,”Biochemistry, 31:14, 4503-4510 (2002).
Braasch et al., “RNA Inteference in Mammalian Cells by Chemically-Modified RNA,”Biochemistry, 42, 7967-7975 (2003).
Caplen, Natasha J., “RNAi as a gene therapy approach,”Expert Opin. Biol. Ther., 3(4):575-586 (2003).
Chiu et al., “siRNA function in RNAi: A chemical modification analysis,” RNA, 9:1034-1048 (2003).
Claverie, Jean-Michel, “Fewer Genes, More Noncoding RNA,”Science, 309, 1529-1530 (2005).
Clemens et al., “The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function,”Journal of Interferon and Cytokine Research, 17:503-524 (1997).
Czech, Michael P., “MicroRNAs as Therapeutic Targets,”The New England Journal of Medicine, 354, 1194-1195 (2006).
Elbashir et al., “Analysis of gene function in somatic mammalian cells using small interfering RNAs,&#x
Jadhav Vasant
Zinnen Shawn
Chong Kimberly
Sirna Therapeutics, Inc.
LandOfFree
RNA interference mediated inhibition of gene expression... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with RNA interference mediated inhibition of gene expression..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and RNA interference mediated inhibition of gene expression... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4171986